Market Insight - Advanced therapies regulation: perspectives from the EU
This article was originally published in Scrip
The human body has become an important source for components of pharmaceuticals and medical devices used to treat diseases and malfunctions. Increasingly, these so-called "advanced therapies" are being developed from blood, cells, skin, bone and human tissues. Their use has revolutionised the treatment of several diseases and injuries, such as cancer, Parkinson's disease, burns and cartilage injuries.
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.